Skip to content

Quick ratio at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
0.0×
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
0.7×-0.2×
PTH
Pelthos Therapeutics Inc.PTHS
1.9×+1.7×
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
2.5×-0.9×
HRO
HarrowHROW
2.3×+1.4×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
6.8×+0.9×

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M
Free cash flow-$6.0M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%
FCF margin-43%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Calculated from Journey Medical Corporation’s reported figures.

Based on the most recent quarter.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's quick ratio?
Journey Medical Corporation (DERM) reported quick ratio of 1.5× in Q1 2026.
How has Journey Medical Corporation's quick ratio changed year-over-year?
Journey Medical Corporation's quick ratio increased by 42.7% year-over-year, from 1× to 1.5×.
What is the long-term trend for Journey Medical Corporation's quick ratio?
Over 5 years (2020 to 2025), Journey Medical Corporation's quick ratio has grown at a 4.9% compound annual growth rate (CAGR), from 1.2× to 1.5×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.